Dianthus Therapeutics Inc Financials
This page shows Dianthus Therapeutics Inc (DNTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded drug development dominates the model, with capital raises expanding the balance sheet faster than the company spends on R&D.
From FY2023 to FY2025, operating cash burn rose from$36.9M to$129.1M . Even so, total assets expanded from$179.4M to$530.9M because annual financing inflows kept outrunning spending, showing a business funded primarily by new capital rather than customer receipts.
With revenue only
The balance sheet remains equity-heavy: FY2025 liabilities were just
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Dianthus Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Dianthus Therapeutics Inc scores 86.31, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.5B) relative to total liabilities ($37.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Dianthus Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Dianthus Therapeutics Inc generates $0.80 in operating cash flow (-$129.1M OCF vs -$162.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Dianthus Therapeutics Inc generated $2.0M in revenue in fiscal year 2025. This represents a decrease of 67.3% from the prior year.
Dianthus Therapeutics Inc's EBITDA was -$177.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 74.7% from the prior year.
Dianthus Therapeutics Inc reported -$162.3M in net income in fiscal year 2025. This represents a decrease of 91.1% from the prior year.
Dianthus Therapeutics Inc earned $-4.20 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 64.7% from the prior year.
Cash & Balance Sheet
Dianthus Therapeutics Inc held $51.1M in cash against $0 in long-term debt as of fiscal year 2025.
Dianthus Therapeutics Inc paid $0.00 per share in dividends in fiscal year 2025.
Dianthus Therapeutics Inc had 43M shares outstanding in fiscal year 2025. This represents an increase of 38.9% from the prior year.
Margins & Returns
Dianthus Therapeutics Inc's operating margin was -8739.3% in fiscal year 2025, reflecting core business profitability. This is down 7105.6 percentage points from the prior year.
Dianthus Therapeutics Inc's net profit margin was -7973.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 6610.6 percentage points from the prior year.
Dianthus Therapeutics Inc's ROE was -32.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 8.8 percentage points from the prior year.
Capital Allocation
Dianthus Therapeutics Inc invested $145.6M in research and development in fiscal year 2025. This represents an increase of 75.2% from the prior year.
DNTH Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $463K+63.0% | $284K-28.3% | $396K+105.2% | $193K-83.4% | $1.2M-12.3% | $1.3M-39.0% | $2.2M+16.6% | $1.9M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $34.5M-42.4% | $59.9M+84.4% | $32.5M+23.8% | $26.3M-2.8% | $27.0M+2.2% | $26.4M+3.4% | $25.5M+41.4% | $18.1M |
| SG&A Expenses | $12.5M+25.6% | $9.9M+21.2% | $8.2M-7.6% | $8.9M+20.9% | $7.3M+7.4% | $6.8M+4.6% | $6.5M+8.9% | $6.0M |
| Operating Income | -$46.5M+33.1% | -$69.5M-72.6% | -$40.3M-15.3% | -$34.9M-5.3% | -$33.2M-4.0% | -$31.9M-6.7% | -$29.9M-34.7% | -$22.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$40.8M+36.6% | -$64.4M-75.3% | -$36.8M-16.2% | -$31.6M-7.2% | -$29.5M-3.8% | -$28.4M-13.0% | -$25.2M-43.0% | -$17.6M |
| EPS (Diluted) | $-0.85 | N/A | $-0.97-10.2% | $-0.88-7.3% | $-0.82 | N/A | $-0.74-45.1% | $-0.51 |
DNTH Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+134.9% | $530.9M-8.1% | $577.4M+77.1% | $326.1M-6.5% | $348.6M-6.8% | $374.0M+5.6% | $354.2M-4.0% | $369.0M |
| Current Assets | $1.1B+173.5% | $409.4M-1.1% | $413.8M+57.0% | $263.6M-2.7% | $271.0M-3.5% | $280.9M-2.3% | $287.5M-21.4% | $365.7M |
| Cash & Equivalents | $627.7M+1128.6% | $51.1M-8.7% | $56.0M+322.9% | $13.2M+30.9% | $10.1M-55.6% | $22.8M-32.3% | $33.7M-89.3% | $314.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.2M+2265.4% | $52K-99.0% | $5.0M+12720.5% | $39K-96.1% | $1.0M | $0-100.0% | $1.4M+65.5% | $840K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $45.6M+21.5% | $37.5M+21.1% | $31.0M+34.8% | $23.0M+15.1% | $20.0M-7.2% | $21.5M+31.7% | $16.4M+52.2% | $10.7M |
| Current Liabilities | $38.3M+24.6% | $30.7M+28.8% | $23.9M+18.7% | $20.1M+18.5% | $17.0M-8.1% | $18.5M+17.5% | $15.7M+56.6% | $10.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.2B+143.5% | $493.4M-9.7% | $546.5M+80.3% | $303.1M-7.8% | $328.6M-6.8% | $352.5M+4.3% | $337.9M-5.7% | $358.2M |
| Retained Earnings | -$377.6M-12.1% | -$336.7M-23.7% | -$272.3M-15.6% | -$235.5M-15.5% | -$203.9M-16.9% | -$174.4M-19.5% | -$146.0M-20.8% | -$120.8M |
DNTH Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.9M+38.6% | -$47.0M-53.8% | -$30.6M-27.9% | -$23.9M+13.5% | -$27.6M-0.7% | -$27.4M-29.0% | -$21.3M-46.4% | -$14.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$134.0M-460.1% | $37.2M+118.5% | -$201.3M-861.1% | $26.4M+78.8% | $14.8M+164.0% | -$23.1M+91.1% | -$259.4M-22286.8% | $1.2M |
| Financing Cash Flow | $739.4M+15042.5% | $4.9M-98.2% | $274.5M+48229.8% | $568K+252.8% | $161K-99.6% | $39.7M+13304.1% | $296K+113.5% | -$2.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DNTH Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -10050.3%+14435.9pp | -24486.3%-14312.5pp | -10173.7%+7923.1pp | -18096.9%-15244.2pp | -2852.7%-445.8pp | -2406.9%-1030.3pp | -1376.6%-184.8pp | -1191.8% |
| Net Margin | -8819.4%+13867.9pp | -22687.3%-13403.2pp | -9284.1%+7104.0pp | -16388.1%-13850.6pp | -2537.5%-392.7pp | -2144.8%-985.8pp | -1159.0%-213.9pp | -945.1% |
| Return on Equity | -3.4%+9.7pp | -13.1%-6.3pp | -6.7%+3.7pp | -10.4%-1.5pp | -9.0%-0.9pp | -8.1%-0.6pp | -7.4%-2.5pp | -4.9% |
| Return on Assets | -3.3%+8.9pp | -12.1%-5.8pp | -6.4%+3.3pp | -9.7%-1.2pp | -8.5%-0.9pp | -7.6%-0.5pp | -7.1%-2.3pp | -4.8% |
| Current Ratio | 29.25+15.9 | 13.32-4.0 | 17.35+4.2 | 13.12-2.9 | 15.99+0.8 | 15.22-3.1 | 18.30-18.2 | 36.46 |
| Debt-to-Equity | 0.04-0.0 | 0.08+0.0 | 0.06-0.0 | 0.08+0.0 | 0.060.0 | 0.06+0.0 | 0.05+0.0 | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Dianthus Therapeutics Inc's annual revenue?
Dianthus Therapeutics Inc (DNTH) reported $2.0M in total revenue for fiscal year 2025. This represents a -67.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dianthus Therapeutics Inc's revenue growing?
Dianthus Therapeutics Inc (DNTH) revenue declined by 67.3% year-over-year, from $6.2M to $2.0M in fiscal year 2025.
Is Dianthus Therapeutics Inc profitable?
No, Dianthus Therapeutics Inc (DNTH) reported a net income of -$162.3M in fiscal year 2025, with a net profit margin of -7973.3%.
What is Dianthus Therapeutics Inc's EBITDA?
Dianthus Therapeutics Inc (DNTH) had EBITDA of -$177.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Dianthus Therapeutics Inc's operating margin?
Dianthus Therapeutics Inc (DNTH) had an operating margin of -8739.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Dianthus Therapeutics Inc's net profit margin?
Dianthus Therapeutics Inc (DNTH) had a net profit margin of -7973.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Dianthus Therapeutics Inc's return on equity (ROE)?
Dianthus Therapeutics Inc (DNTH) has a return on equity of -32.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Dianthus Therapeutics Inc's operating cash flow?
Dianthus Therapeutics Inc (DNTH) generated -$129.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Dianthus Therapeutics Inc's total assets?
Dianthus Therapeutics Inc (DNTH) had $530.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Dianthus Therapeutics Inc spend on research and development?
Dianthus Therapeutics Inc (DNTH) invested $145.6M in research and development during fiscal year 2025.
What is Dianthus Therapeutics Inc's current ratio?
Dianthus Therapeutics Inc (DNTH) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Dianthus Therapeutics Inc's debt-to-equity ratio?
Dianthus Therapeutics Inc (DNTH) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dianthus Therapeutics Inc's return on assets (ROA)?
Dianthus Therapeutics Inc (DNTH) had a return on assets of -30.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Dianthus Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Dianthus Therapeutics Inc (DNTH) had $51.1M in cash against an annual operating cash burn of $129.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Dianthus Therapeutics Inc's Altman Z-Score?
Dianthus Therapeutics Inc (DNTH) has an Altman Z-Score of 86.31, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Dianthus Therapeutics Inc's Piotroski F-Score?
Dianthus Therapeutics Inc (DNTH) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dianthus Therapeutics Inc's earnings high quality?
Dianthus Therapeutics Inc (DNTH) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Dianthus Therapeutics Inc?
Dianthus Therapeutics Inc (DNTH) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.